Dyne Therapeutics reports Q3 2026 results, FDA review of DMD drug z-rostudirsen with potential 2027 US launch

Dyne Therapeutics announced its third quarter 2026 financial results and key business updates, including the FDA's priority review of its Duchenne muscular dystrophy (DMD) drug z-rostudirsen, with a target decision date of January 21, 2027. The company expects a potential U.S. launch of z-rostudirsen in early 2027 if approved. Dyne also presented positive one-year clinical data for its myotonic dystrophy type 1 (DM1) drug z-basivarsen and plans topline data from an expansion cohort in early 2027, aiming for a possible U.S. launch in 2028. Financially, Dyne reported a net loss of $193.6 million for Q3 2026, with cash reserves sufficient to fund operations into mid-2028, reflecting increased R&D and administrative expenses linked to clinical trials and commercialization preparations.

Dyne Therapeutics Inc. shares are trading at USD 18.51 on Pluang as of Nov 05, 2026 19:42 WIB, down slightly by 0.16% for the day. The stock has a market cap of $3.46 billion and a 52-week trading range between $14.25 and $26.78. Despite the recent financial loss reported for Q3 2026, investor interest remains balanced with 52% of Pluang orders selling and 48% buying, reflecting cautious engagement ahead of potential drug launches.